Sequential activation of the AKT pathway in human osteoblasts treated with Oscarvit: a bioactive product with positive effect both on skeletal pain and mineralization in osteoblasts

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00013233

Enrollment

Registered

2017-11-06

Start date

2014-10-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M80 M81 M82

Interventions

Group 1: Oscarvit, 3x600 mg/day, for 20 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient is suffering from osteoporoses/osteoarthrosis

Exclusion criteria

Exclusion criteria: There is no participation for patients who are not suffering from osteoporoses/osteoarthrosis

Design outcomes

Primary

Measure	Time frame
After 20 days treatment with OSC (3x600mg/day) the alleviation of pain will be measured by questioning of the patients in accordance with Numeric Pain Rating Scale (NPRS).	—

Secondary

Measure	Time frame
Additional goal criteria for the study was the evaluation of pain after 5- and 10 days treatment with OSC according to NPRS.	—

Countries

Germany

Contacts

Public ContactTibor Görögh

Universitätsklinikum Schleswig-Holstein Hals-,Nasen-,Ohrenklinik, Kopf- und Halschirurgie

gorogh@hno.uni-kiel.de0049-431-500-21850

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 25, 2026